Targets › MPC2
1 program from 1 company in 1 trial: 1 Phase 2; Cardiovascular; next expected readout Sep 2028.
Mediates the uptake of pyruvate into mitochondria to maintain the balance between glycolysis and oxidative phosphorylation. Plays an essential role in cellular metabolism. (UniProt, O95563)
Open in Phaseline: the race on MPC2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Virginia | CIR-0602K mitochondrial pyruvate carrier (MPC) inhibitor | MPC1, MPC2 | Phase 2 | Type 1 Diabetes (T1D) | Sep 2028 |
Type 1 Diabetes (T1D) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.